Recently, ACT of T-cells targeting mutant proteins (SLC3A2, KIAA0368, CADPS2 and CTSB) detected in a patient tumor in combination with interleukin two have been demonstrated to induce tumor regression (Zacharakis et al., 2018). This evidence concerns the gene SLC3A2 and neoplasm.